Suppr超能文献

外泌体:IL-35 基因修饰脂肪间充质干细胞抑制心脏移植后急性排斥反应的潜在执行者。

Exosomes: Potential executors of IL-35 gene-modified adipose-derived mesenchymal stem cells in inhibiting acute rejection after heart transplantation.

机构信息

Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China.

Tianjin General Surgery Institute, Tianjin Medical University General Hospital, Tianjin, China.

出版信息

Scand J Immunol. 2022 Aug;96(2):e13171. doi: 10.1111/sji.13171. Epub 2022 Apr 14.

Abstract

Heart transplantation has become the only 'cure' for end-stage heart diseases, but acute allograft rejection is the major obstacle to the survival of patients. Our previous studies showed that IL-35 gene-modified adipose-derived mesenchymal stem cells (IL-35-ASCs) can effectively inhibit graft rejection and prolong the survival of transplanted hearts in mice. This study further explored the mechanism of IL-35-ASCs, especially focusing on the important role of IL-35-ASC-derived exosomes (IL-35-ASCexos) in inhibiting acute rejection. IL-35-ASCs were constructed in vitro and pretreated with IL-35 neutralizing antibody and GW4869 (an inhibitor of neutral sphingomyelinase that impairs exosome biogenesis/release). Then, pretreated IL-35-ASCs and CD4 T cells were cocultured in Transwell plates, and changes in regulatory T cells (Tregs) and cytokines were detected. Then, IL-35-ASCexos were extracted, identified and analysed, and their immunoregulatory effects on CD4 T cells were studied through coculture experiments. Finally, IL-35-ASCexos were applied to a mouse heart transplantation model to investigate the therapeutic effects on acute rejection of the allograft. The coculture experiment showed that the IL-35-neutralizing antibody could not completely block the immunosuppressive function of IL-35-ASCs, while GW4869 could effectively reduce their immunoregulatory characteristics. Similar to IL-35-ASCs, IL-35-ASCexos also have powerful immunosuppressive properties, effectively upregulating the Treg ratio in vivo and in vitro and prolonging graft survival. As the main effectors of IL-35-ASCs, these findings highlight the therapeutic potential of IL-35-ASCexos in inhibiting acute cardiac rejection of the allograft. Although the specific mechanism remains unclear and needs to be further explored, IL-35-ASCexos therapy is expected to become a new method to inhibit acute graft rejection.

摘要

心脏移植已成为治疗终末期心脏病的唯一“疗法”,但急性移植物排斥反应是影响患者生存的主要障碍。我们之前的研究表明,IL-35 基因修饰的脂肪间充质干细胞(IL-35-ASCs)可有效抑制移植物排斥反应,并延长小鼠移植心脏的存活时间。本研究进一步探讨了 IL-35-ASCs 的作用机制,特别是聚焦于 IL-35-ASC 来源的外泌体(IL-35-ASCexos)在抑制急性排斥反应中的重要作用。我们在体外构建了 IL-35-ASCs,并使用 IL-35 中和抗体和 GW4869(一种抑制中性鞘磷脂酶的抑制剂,可损害外泌体的生物发生/释放)预处理。然后,将预处理的 IL-35-ASCs 和 CD4 T 细胞在 Transwell 板中共培养,并检测调节性 T 细胞(Tregs)和细胞因子的变化。然后,提取、鉴定和分析了 IL-35-ASCexos,并通过共培养实验研究了它们对 CD4 T 细胞的免疫调节作用。最后,将 IL-35-ASCexos 应用于小鼠心脏移植模型,以研究其对同种异体移植物急性排斥反应的治疗作用。共培养实验表明,IL-35 中和抗体不能完全阻断 IL-35-ASCs 的免疫抑制功能,而 GW4869 可以有效降低其免疫调节特性。与 IL-35-ASCs 相似,IL-35-ASCexos 也具有强大的免疫抑制特性,可有效上调体内和体外 Treg 比例,并延长移植物存活时间。作为 IL-35-ASCs 的主要效应物,这些发现突出了 IL-35-ASCexos 在抑制同种异体移植物急性心脏排斥反应中的治疗潜力。尽管具体机制尚不清楚,需要进一步探讨,但 IL-35-ASCexos 治疗有望成为抑制急性移植物排斥反应的新方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验